NTM-Pulmonary Infection - CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Skip to main content

Course Videos

Showing 25 - 36 of 89 results

Previous| 1 | 2 | 3 | 4 | 5 ...8 |Next

What is the role of molecular diagnostics and speciating NTM organisms as part of the microbiological characterization for MAC lung infection?

What is the role of molecular diagnostics and speciating NTM organisms as part of the microbiological characterization for MAC lung infection?

Why is continuous airway clearance an important pillar of therapy for patients with MAC lung disease?

Why is continuous airway clearance an important pillar of therapy for patients with MAC lung disease?

What are the predictors of progressive MAC lung disease and what are the guideline-based (ATS/IDSA/BTS) recommendations for antibiotic treatment in these high-risk patients?

What are the predictors of progressive MAC lung disease and what are the guideline-based (ATS/IDSA/BTS) recommendations for antibiotic treatment in these high-risk patients?

What clinical findings absolutely mandate antibiotic treatment for individuals with culture-positive MAC lung disease? What is the gray area?

What clinical findings absolutely mandate antibiotic treatment for individuals with culture-positive MAC lung disease? What is the gray area?

What are the relevance, role, and clinical importance of obtaining and documenting in vitro culture drug sensitivity testing to antibiotics considered for treatment of MAC lung disease?

What are the relevance, role, and clinical importance of obtaining and documenting in vitro culture drug sensitivity testing to antibiotics considered for treatment of MAC lung disease?

What are the most effective methods for sputum induction and microbiologic sampling? And, in your experience, in what percentage of cases is a bronchoscopy or lung biopsy necessary to achieve microbiologic confirmation of MAC lung disease?

What are the most effective methods for sputum induction and microbiologic sampling? And, in your experience, in what percentage of cases is a bronchoscopy or lung biopsy necessary to achieve microbiologic confirmation of MAC lung disease?

What is it about the non-specific symptomatology that characterizes the broad clinical spectrum of MAC lung disease that creates diagnostic challenges for the clinician?

What is it about the non-specific symptomatology that characterizes the broad clinical spectrum of MAC lung disease that creates diagnostic challenges for the clinician?

Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

$Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?$ Video

Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?

What are the specific recommendations and concrete guidelines—albeit 12 years old—for treatment for MAC lung disease? Is there flexibility as far as dosing frequency?

What are the specific recommendations and concrete guidelines—albeit 12 years old—for treatment for MAC lung disease? Is there flexibility as far as dosing frequency?

Showing 25 - 36 of 89 results

Previous| 1 | 2 | 3 | 4 | 5 ...8 |Next